Main objective: Perform a genome wide association analysis on remission of asthma in a cohort of subjects who were previously diagnosed as having asthma. Secondary objective: Perform genetic association studies between asthma remission and (pathways…
ID
Source
Brief title
Condition
- Bronchial disorders (excl neoplasms)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Presence of complete asthma remission: no current asthma symptoms (asthma
attacks, wheeze), no current use of asthma medication, FEV1 pre bronchodilator
> 80% predicted, no bronchial hyperresponsiveness (PC20 histamine > 32 mg/ml).
Associations between the single nucleotide polymorphisms genotyped in the GWA
study and the presence of complete asthma remission will be studied using
logistic regression analysis.
Secondary outcome
NA
Background summary
Recently, we have shown that some asthmatics show complete asthma remission in
adulthood. Investigating the mechanisms leading to this spontaneous remission
of asthma may provide new avenues for better understanding of asthma remission
and may eventually lead to new intervention strategies. In 2008 we have started
a genome wide association study (GWAs) on asthma. Some of the patients in this
GWA study will now be in complete asthma remission.
Study objective
Main objective: Perform a genome wide association analysis on remission of
asthma in a cohort of subjects who were previously diagnosed as having asthma.
Secondary objective: Perform genetic association studies between asthma
remission and (pathways of) candidate genes.
Study design
A follow-up study on all asthmatic participants of the GWA study on asthma.
Participants have to fill in a postal questionnaire and those subjects
in clinical remission (no asthma symptoms and no use of asthma medication) will
be invited to the UMCG to perform spirometry and a histamine provocation test.
Study burden and risks
This study will provide insight in the mechanisms leading to asthma remission.
This has no personal benefit to the individual participant, however it will be
important for future putative preventive measures or intervention to cure
asthma. The burden to the individual participant will be performing spirometry
and a histamine challenge test. This implies that the person may experience
some breathlessness that will fade away immediately after giving a
bronchodilator. However, since these individuals will most likely not respond
at all, they will not have any side effect whatsoever.
Postbus 30001
9700 RB Groningen
NL
Postbus 30001
9700 RB Groningen
NL
Listed location countries
Age
Inclusion criteria
1. Age 18 years or older.
2. Previous diagnosis of asthma
3. Included in the GWA-study on asthma ;Additional inclusion criteria for the performance of spirometry and a histamine provocation test:
4. No current asthma symptoms
5. No use of asthma medication
Exclusion criteria
1. Presence of serious concomittant diseases
2. Pregnancy
Additional exclusion criterium for histamine provocation testing:
3. FEV1 lower than 1.2 L
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL34958.042.10 |